⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38657136 | 1.00 | — | — | |
| SCHEMBL22465749 | 0.81 | — | — | |
| SCHEMBL29479539 | 0.77 | — | — | |
| SCHEMBL191846 | 0.77 | — | — | |
| SCHEMBL30780302 | 0.77 | KMT2A (0.34) | — | |
| SCHEMBL6307027 | 0.75 | — | — | |
| SCHEMBL30097067 | 0.75 | — | — | |
| SCHEMBL13016652 | 0.75 | — | — | |
| SCHEMBL191637 | 0.75 | — | — | |
| SCHEMBL29801557 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049604-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | claimed |
| US-12590102-B2 | Compound and organic light emitting device comprising the same | LG CHEM, LTD. (KR) | 2026-03-31 | — | — | US | disclosed |
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4615581-A2 | FUSED MULTICYCLIC COMPOUNDS AND THEIR USE AS PARP1 INHIBITORS | Laekna Pharmaceutical Ningbo Co., Ltd. (CN) | 2025-09-17 | — | — | EP | disclosed |
| US-12384777-B2 | Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts | Tay Therapeutics Limited (GB) | 2025-08-12 | — | — | US | disclosed |
| EP-4554938-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-119894879-A | Tyrosine kinase 2 inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119768400-A | Fused ring compound, application thereof and pharmaceutical composition containing fused ring compound | 苏州信诺维医药科技股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| EP-1694677-B1 | SPIROPIPERIDINE DERIVATIVES FOR CONTROLLING PESTS | SYNGENTA PARTICIPATIONS AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| CN-101544640-A | Spiropiperidine derivatives for controlling pests | SYNGENTA PARTICIPATIONS AG | 2009-09-30 | — | — | CN | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2007089512-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20070135408-A1 | Spiropiperidine derivatives for controlling pests | SYNGENTA CROP PROTECTION, INC. | 2007-06-14 | — | — | US | disclosed |
| CN-1894249-A | Spiropiperidine derivatives for controlling pests | SYNGENTA PARTICIPATIONS AG (CH) | 2007-01-10 | — | — | CN | disclosed |
| EP-1694677-A1 | SPIROPIPERIDINE DERIVATIVES FOR CONTROLLING PESTS | Syngenta Participations AG (CH) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005061500-A1 | SPIROPIPERIDINE DERIVATIVES FOR CONTROLLING PESTS | SYNGENTA PARTICIPATIONS AG (CH) | 2005-07-07 | — | — | WO | disclosed |